Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.64 USD
Change Today -0.09 / -3.30%
Volume 583.3K
BIOC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

biocept inc (BIOC) Snapshot

Open
$2.74
Previous Close
$2.73
Day High
$2.74
Day Low
$2.60
52 Week High
07/10/14 - $6.68
52 Week Low
02/10/15 - $1.09
Market Cap
47.3M
Average Volume 10 Days
889.6K
EPS TTM
$-2.78
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCEPT INC (BIOC)

Related News

No related news articles were found.

biocept inc (BIOC) Related Businessweek News

No Related Businessweek News Found

biocept inc (BIOC) Details

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options; OncoCEE-LU, a test for non-small cell lung cancer; and OncoCEE-GA for gastric cancer. The company is also developing other OncoCEE CTC tests, including OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma, as well as CEE-Selector, a sequencing application for various cancer types. It sells its cancer diagnostic tests directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. The company was founded in 1997 and is headquartered in San Diego, California.

42 Employees
Last Reported Date: 03/11/15
Founded in 1997

biocept inc (BIOC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $418.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $255.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $208.2K
Vice President of Commercial Operations
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2014.

biocept inc (BIOC) Key Developments

Biocept Expands Blood-Based Test Menu to Identify Key Biomarker for Breast Cancer and Non-Small Cell and Small Cell Lung Cancers

Biocept, Inc. announced the launch of its FGFR1 amplification testing utilizing a patient's blood sample. This diagnostic assay has the potential to help physicians identify patients who may be receptive to certain breast and lung cancer treatments. Studies have demonstrated FGFR1 amplification as a driver for uncontrolled cell growth. Hence treatments targeting this pathway are being evaluated in a number of clinical trials currently underway. Small cell lung cancer accounts for 10 to 15% of all lung cancers and has a five-year survival rate, which is less than half that of non-small cell lung cancer. Because small cell lung cancer shows symptoms much later than non-small cell lung cancer, it is typically diagnosed much later in the course of the disease after it has metastasized to other parts of the body.

Biocept, Sarah Cannon Research Institute Collaborate to Focus on Screening ER+ Breast Cancer Patients

Biocept entered into a clinical collaboration with Sarah Cannon Research Institute. The company said that the collaboration aims to determine the clinical utility of detecting biomarkers present in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in blood samples for estrogen positive (ER+) breast cancer patients using Biocept's OncoCEE technology.

Biocept, Inc. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 01:00 PM

Biocept, Inc. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 01:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Michael W. Nall, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.64 USD -0.09

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.15 USD -0.03
BioMerieux €96.11 EUR -0.16
Fluidigm Corp $22.93 USD -0.50
Illumina Inc $220.07 USD -0.61
Laboratory Corp of America Holdings $120.75 USD -1.44
View Industry Companies
 

Industry Analysis

BIOC

Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 107.3x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 90.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.